Table 2

Demographic Characteristics

Safety population

AC-1202

N = 86

Placebo

N = 66


Age

Mean (± SD)

Median

76.9 (± 8.9)

78.0

76.8 (± 7.4)

78.0

Range

(52 – 93)

(51 – 89)


Height (cms)

Mean (± SD)

165.2 (± 11.4)

163.2 (± 16.4)

Median

163.8

164.6

Range

(142.2 – 190.1)

(114.3 – 185.4)


Weight (kg)

Mean (± SD)

69.0 (± 15.15)

70.6 (± 13.7)

Median

69.2

67.8

Range

(34.3 – 100.2)

(47.6 – 100.2)


Sex n (%)

Male

36 (41.7)

31 (47.0)

Female

50 (58.1)

35 (53.0)


Race n (%)

Caucasian

78 (90.7)

61 (92.4)

Black

1 (1.2)

0

Hispanic

7 (8.1)

5 (7.6)


Level of Education n (%)

Graduate/Professional Training

17 (19.8)

7 (10.6)

Some college

15 (17.4)

17 (25.8)

High School

49 (57.0)

34 (51.5)

Grade School

5 (5.8)

8 (12.1)


AD medications n (%)*

Aricept™

43 (50)

28 (42.4)

Exelon™

11 (12.8)

11 (16.7)

Namenda™

32 (37.2)

31 (47)

Reminyl™/Razadyne™

3 (3.5)

9 (13.6)


Genotyped population

AC-1202

N = 67

Placebo

N = 57


APOE Genotype n (%)

3/2

4 (6.0)

2 (3.5)

3/3

25 (37.3)

24 (42.1)

4/2

4/3

3 (4.9)

31 (46.3)

0

21 (36.8)

4/4

4 (6.0)

10 (17.5)

Total E4(+)

38 (56.7)

31 (54.4)

Total E4(-)

29 (43.3)

26 (45.6)


ITT population

AC-1202

N = 77

Placebo

N = 63


Baseline MMSE

Mean (± SD)

19.68 (± 4.48)

19.48 (± 4.37)

Median

20.00

20.00

Range

(10 – 28)

(8 – 29)

95% CI

18.66, 20.69

18.37, 20.58


Baseline ADAS-Cog

Mean (± SD)

23.88 (± 9.17)

23.35 (± 8.7)

Median

23.67

23.00

Range

(7.00 – 54.33)

(11.33 – 62.00)

95% CI

21.80, 25.96

21.16, 25.54


*Some participants were on more than one AD medication

Henderson et al. Nutrition & Metabolism 2009 6:31   doi:10.1186/1743-7075-6-31

Open Data